138 related articles for article (PubMed ID: 35267664)
1.
Lin TY; Yang CH; Chou HC; Cheng CM; Liu YW; Wang JY; Huang LR; Tsai SF; Huang SF; Chen YR
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267664
[TBL] [Abstract][Full Text] [Related]
2. Molecular structure, expression, and functional role of Clec11a in skeletal biology and cancers.
Wang M; Guo J; Zhang L; Kuek V; Xu J; Zou J
J Cell Physiol; 2020 Oct; 235(10):6357-6365. PubMed ID: 32003015
[TBL] [Abstract][Full Text] [Related]
3. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
4. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
6. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
7. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
8. Clec11a/osteolectin is an osteogenic growth factor that promotes the maintenance of the adult skeleton.
Yue R; Shen B; Morrison SJ
Elife; 2016 Dec; 5():. PubMed ID: 27976999
[TBL] [Abstract][Full Text] [Related]
9. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity.
Fujiwara M; Muragaki Y; Ooshima A
Arch Dermatol Res; 2005 Oct; 297(4):161-9. PubMed ID: 16184401
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression.
Deroanne CF; Hajitou A; Calberg-Bacq CM; Nusgens BV; Lapière CM
Cancer Res; 1997 Dec; 57(24):5590-7. PubMed ID: 9407972
[TBL] [Abstract][Full Text] [Related]
12. Human umbilical cord mesenchymal stromal cells-derived extracellular vesicles exert potent bone protective effects by CLEC11A-mediated regulation of bone metabolism.
Hu Y; Zhang Y; Ni CY; Chen CY; Rao SS; Yin H; Huang J; Tan YJ; Wang ZX; Cao J; Liu ZZ; Xie PL; Wu B; Luo J; Xie H
Theranostics; 2020; 10(5):2293-2308. PubMed ID: 32089743
[TBL] [Abstract][Full Text] [Related]
13. Tumorigenicity depends on angiogenic potential of tumor cells: dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells.
Aonuma M; Iwahana M; Nakayama Y; Hirotani K; Hattori C; Murakami K; Shibuya M; Tanaka NG
Angiogenesis; 1998; 2(1):57-66. PubMed ID: 14517376
[TBL] [Abstract][Full Text] [Related]
14. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Kudo K; Ohashi K; Makimoto G; Higo H; Kato Y; Kayatani H; Kurata Y; Takami Y; Minami D; Ninomiya T; Kubo T; Ichihara E; Sato A; Hotta K; Yoshino T; Tanimoto M; Kiura K
Mol Oncol; 2017 Jun; 11(6):670-681. PubMed ID: 28388009
[TBL] [Abstract][Full Text] [Related]
15. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.
Yang CH; Chou HC; Fu YN; Yeh CL; Cheng HW; Chang IC; Liu KJ; Chang GC; Tsai TF; Tsai SF; Liu HP; Wu YC; Chen YT; Huang SF; Chen YR
Biochim Biophys Acta; 2015 Jul; 1852(7):1540-9. PubMed ID: 25912735
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Lee JG; Wu R
Neoplasia; 2015 Feb; 17(2):190-200. PubMed ID: 25748238
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
18. The mineral dust-induced gene,
Zhou H; Geng F; Chen Y; Du J; Zhang X; Liu B; Song D; Hou H; Zhao H
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760153
[TBL] [Abstract][Full Text] [Related]
19. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells.
Yeo CD; Kim YA; Lee HY; Kim JW; Lee SH; Kim SJ; Kwon SS; Kim YH; Kim SC
Exp Lung Res; 2017 Feb; 43(1):29-37. PubMed ID: 28394654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
